nasal swabs
PreclinicalBiologic
nasal swabs is one of 11 biologic programs targeting Dialysis Patients. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
13 competitors in Dialysis Patients
#DrugCompanyPhaseTrials
1Betadine
BBecton, Dickinson and Company
Approved
Sodium Valproate
AstraZenecaPhase 3
Evrenzo
AstellasPhase 2
KN060
SSuzhou Alphamab Co., Ltd.
Phase 2
Tirosint
IInstitut Jerome Lejeune
Preclinical
Deca-Durabolin
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Tegopen
Bristol-Myers SquibbPreclinical
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Triferic
RRockwell Medical Technologies, Inc.
Preclinical
nasal swabs
CCentre Hospitalier Universitaire de Saint Etienne
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Dialysis Patients1 trial
Ex Vivo Evaluation of Immunity Activation Face to S. Aureus Antigens and Adjuvants of a Vaccine Candidate in Cells From Haemodialysis Patients
Completed·—·N/A·NCT03643328·50 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for nasal swabs. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details